Investor Presentation Q1 2018 Audited Results

III Key Investment Highlights 6 Robust Financial Performance Robust financial performance with double digit top line and bottom line growth Gross Revenue¹ | EGP mn CAGR 31% 9,818 7,372 5,439 4,302 3,361 Gross Profit | EGP mn, % CAGR 37% 8.6% 7.9% 7.8% 7.5% 7.2% 7.3% 826 6.8% 569 YOY↑ 51% 394 2,958 307 1,953 228 EBITDA & Margin | EGP mn, % CAGR 46% 4.2% IN 406 3.2% 3.2% 2.9% 2.9% 2.9% 2.7% 229 YOY↑ 45% YoY 69% 155 122 216 89 92 149 55 2013 2014 2015 2016 2017 1Q17 1Q18 2013 2014 2015 2016 2017 1Q17 1Q18 2013 2014 2015 2016 2017 1Q17 1Q18 Net Profit & Margin | EGP mn, % ROE | % CAGR 50% 1.8% Includes one-time capital inc. expenses of EGP 7.5 mn& general provision of EGP 3.5 mn 41% 36% 1.4% 32% 33% 170 1.1% 1.0% 1.0% 1.0% 0.9% 102 YoY 46% 57 35 38 28 19 47% Return on Fixed Assets | % In equity from IPO proceeds 48% 42% 37% 7% 5% 63% 89% 11% 13% 2013 2014 2015 2016 2017 1Q17 1Q18 2013 2014 2015 2016 2017 1Q17 1Q18 2013 2014 2015 2016 2017 1Q17 1Q18 ibnsinapharma Source: Company Management (1): Pro forma gross revenue includes part of 3PL revenue that was stated as other income until 2016 18

View entire presentation